Status:
TERMINATED
Continuous Glucose Monitoring to Aid Weight Loss in Prediabetes
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Weight Loss
PreDiabetes
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
The primary objective of this study is to determine whether intermittent use of continuous glucose monitor will facilitate weight loss in individuals who are overweight/obese with prediabetes.
Detailed Description
Continuous glucose monitoring (CGM) has revolutionized the treatment of patients on intensive insulin therapy and its utility can also be harnessed to help individuals with prediabetes make healthful ...
Eligibility Criteria
Inclusion
- Overweight/obese (BMI 25-40 kg/m2)
- Prediabetes (fasting glucose 100-125 mg/dL and/or HbA1c 5.7-6.4%)
Exclusion
- On glucose-lowering medications (e.g., metformin)
- On weight-loss medications
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03844646
Start Date
August 1 2019
End Date
December 31 2021
Last Update
January 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford
Stanford, California, United States, 94305